SecBot SecBot

OCGN drug pipeline

Ocugen, Inc. · 2 rated drugs
$0.7730
−6.6% 1-day · Nov 16
Next catalyst
2027
OCU410ST BLA filing
Typical move on FDA news
±2.2%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 mixed
Phase 3 trials
1
0 with results posted

Upcoming catalysts

2 dated
  1. 2027
    OCU410ST
    BLA filing · Stargardt Disease
  2. Feb 12, 2027
    Phase 3 primary completion

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2/3 (pivotal confirmatory)
Time to marketIf the Phase 2/3 topline data in Q2 2027 is positive, Ocugen plans a BLA submission by mid-2027, followed by a standard FDA review period of roughly 10-12 months, suggesting a potential approval decision in the second half of 2028 at the earliest.

OCU410ST AAV5-hRORA Updated Nov 5

2027
Next catalyst
BLA filing · 2027 · Stargardt Disease
What to watch

The next hard catalyst for OCU410ST is the Phase 2/3 GARDian3 topline data readout expected in Q2 2027 (roughly 5-7 months from now). If the 12-month data confirms the Phase 1 signal (54% lesion reduction, +6-letter BCVA gain), Ocugen plans a BLA submission by mid-2027, which would be a major revaluation event. If the data disappoints or shows no statistical separation, the stock could fall sharply given the 31.6% short interest. The DMC's recommendation to continue without modification after the interim analysis is mildly reassuring but not efficacy-confirming.

Bull case
  • No FDA-approved treatment exists for Stargardt disease, a rare inherited retinal condition affecting over 100,000 patients in the U.S. and EU, representing a large unmet medical need.
  • Phase 1 GARDian1 data published in Nature Eye (Jan 2026) showed a 54% reduction in atrophic lesion growth in treated vs fellow eyes, +6-letter BCVA gain, and 48% slower lesion expansion with a favorable safety profile.
  • Phase 2/3 GARDian3 enrollment and dosing completed early (63 patients in under 9 months), indicating strong patient and investigator demand.
Bear case
  • Very high short interest: 31.6% of outstanding shares short as of Oct 15, 2026, with 15.79 days to cover, reflecting heavy bearish positioning.
  • CEO Shankar Musunuri sold approximately $1.0 million of stock in September and October 2026 via 10b5-1 plans at $0.95-$1.12 per share, well below the analyst mean price target.
  • The Q3 2026 interim analysis was inconclusive: the DMC recommended continuing without modification, but management acknowledged small patient numbers, early 8-month timepoint, and heterogeneous baseline characteristics limited the readout.
▲ bullish
Impact
PhasePhase 3
Time to marketPotential FDA approval in 2027-2028 if Phase 3 succeeds and BLA submission (targeted Q3 2026 rolling) is accepted.

OCU400 aav5-hnr2e3 gene therapy Updated Jul 13

What to watch

Watch for the rolling BLA submission in Q3 2026 as a validation event and the Phase 3 topline readout in Q1 2027 as the primary binary catalyst. The stock has strong institutional accumulation and analyst support (9 Buy, mean PT ~$11.43 vs ~$1.43), but remains pre-revenue with high dilution risk from $130M convertible notes. The Phase 1/2 data was encouraging, durability and a gene-agnostic approach differentiate OCU400 from the only approved therapy, Luxturna.

Bull case
  • Gene-agnostic approach differentiates OCU400 from Luxturna (the only approved RP gene therapy), which treats only RPE65 mutations, OCU400 could address many of the ~100 known RP-causing mutations, expanding the addressable market dramatically.
  • Phase 1/2 data showed durable safety and meaningful visual function improvements sustained through 2-3 year follow-up, de-risking the mechanism.
  • Phase 3 liMeliGhT trial is >95% powered assuming only 50% response rate (based on Phase 1/2 data showing 62.5% of relevant patients met responder criteria).
Bear case
  • Phase 3 topline data (Q1 2027) is the defining binary event, a Phase 3 failure would be catastrophic for a pre-revenue company that has yet to generate significant product sales.
  • Rolling BLA submission in Q3 2026 before Phase 3 data readout is an unusual strategy that could face FDA pushback if interim data doesn't support accelerated submission.
  • Pre-revenue biotech with consistent losses, Q1 2026 net loss of $19.2M (6c/share, missing consensus by 1c) requires continued capital markets access.

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Jan 1, 2026OCU400Breakthrough designation+2.2%+10.4%
Jan 1, 2026OCU400Orphan drug designation+2.2%+10.4%
Jun 1, 2025OCU410STApproval+0.1%+26.8%
Jan 1, 2025OCU410STOrphan drug designation+11.8%+3.2%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
—A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis PigmentosaPhase 3Active not recruiting140Feb 12, 2027